Participants were also assessed utilizing the Barnes Akathisia Ratings Scale (BARS) for akathisia and the Simpson-Angus Scale
(SAS) for parkinsonism.
In addition, 7% experienced treatment-emergent extrapyramidal symptoms as defined by a Simpson-Angus Scale
score of 3 or less at baseline rising to greater than 3 on treatment.
Extrapyramidal symptoms were evaluated using the Simpson-Angus scale
(Simpson and Angus 1979), Barnes Akathisia scale (Barnes 1989), and abnormal involuntary movement scale (AIMS) (National Institute of Mental Health 1976b).
Tolerability was measured using the Simpson-Angus Scale
(SAS) and various laboratory measurements
The safety and efficacy of intramuscular ziprasidone were evaluated by using the following instruments: Behavioral Activity Rating Scale (BARS) (responders were defined a priori as having a [greater than or equal to] 2-point reduction in BARS score); Clinical Global Impressions, severity of illness (CGI-S) and global improvement (CGI-I) scales; Positive and Negative Syndrome Scale (PANSS); Barnes Akathisia Scale (BAS); and Simpson-Angus Scale
Participants were assessed utilizing the Barnes Akathisia Ratings Scale (BARS) for akathisia and the Simpson-Angus Scale
(SAS) for parkinsonism.
Participants will be randomized to 100 mg/day of amisulpride or placebo for 12 weeks, with the primary outcomes being change in the Brief Psychiatric Rating Scale, a quality of life measure, and the Simpson-Angus Scale
of Parkinsonian symptoms.
At the same time, they assessed adverse events using the Simpson-Angus Scale
, Barnes Akathisia Rating Scale, and the Abnormal Involuntary Movement Scale.
Patients treated with haloperidol also experienced a significant increase in extrapyramidal symptoms (EPS) compared to aripiprazole patients, as measured by mean change from baseline to endpoint in the Simpson-Angus Scale
Safety and tolerability were assessed by the Modified Simpson-Angus Scale
(SAS) and the Barnes Akathisia Rating Scale (BARS), where results showed fewer patients on SEROQUEL experienced EPS and akathisia than those on mood stabilizers alone.
No significant changes were observed in Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale
(SAS), or Barnes Akathisia Scale (BAS) at baseline and at the end of the study.
Safety and tolerability were also assessed weekly using the Simpson-Angus Scale
(SAS), Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), laboratory tests and vital signs.